SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C.  20549

                                    FORM 10-Q

                  Quarterly Report Under Section 13 or 15(d) of
                       The Securities Exchange Act of 1934



For quarter ended: March 31, 2000                    Commission File No. 0-11178
                                                                         -------


                           UTAH MEDICAL PRODUCTS, INC.
                           ---------------------------
             (Exact name of Registrant as specified in its charter)


           UTAH                                                 87-0342734
     -----------------                                       ---------------
(State  or  other  jurisdiction  of                         (I.R.S.  Employer
 incorporation  or  organization)                          Identification  No.)


                               7043 South 300 West
                              Midvale, Utah  84047
                        --------------------------------
                     Address of principal executive offices


Registrant's  telephone  number:     (801)  566-1200
                                     ---------------


     Indicate  by  check  mark  whether the registrant (1) has filed all reports
required  to  be filed by Sections 13 or 15(d) of the Securities Exchange Act of
1934  during  the  preceding  12  months  (or  for  such shorter period that the
registrant  was required to file such reports) and; (2) has been subject to such
filing  requirements  for  the  past  90  days.      Yes  X     No
                                                          -

  The  number  of  shares outstanding of the registrant's common stock as of May
10,  2000:  6,390,011
            ---------

<PAGE>
                           UTAH MEDICAL PRODUCTS, INC.
                           ---------------------------

                               INDEX TO FORM 10-Q
                               ------------------

PART  I  -  FINANCIAL  INFORMATION                                        PAGE
                                                                          ----

  Item  1.  Financial  Statements

     Consolidated  Condensed  Balance  Sheets  as  of
     March  31,  2000  and  December  31,  1999                             1

     Consolidated  Condensed  Statements  of  Income  for  the
     three  months  ended  March  31,  2000  and  March  31,  1999          2

     Consolidated  Condensed  Statements  of  Cash  Flows  for  the
     three  months  ended  March  31,  2000  and  March  31,  1999          3

     Notes  to  Consolidated  Condensed  Financial  Statements              4


  Item  2.  Management's  Discussion  and  Analysis  of
             Financial  Condition  and  Results  of  Operations             6

PART  II  -  OTHER  INFORMATION

  Item  6.  Exhibits  and  Reports  on  Form  8-K                           9


SIGNATURES                                                                  9

<PAGE>

                        PART I  -  FINANCIAL INFORMATION

ITEM  1.  FINANCIAL  STATEMENTS


                  UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES
                  --------------------------------------------
                   CONSOLIDATED CONDENSED BALANCE SHEETS AS OF
                   -------------------------------------------
                      MARCH 31, 2000 AND DECEMBER 31, 1999
                      ------------------------------------
                           (in thousands - unaudited)
<TABLE>
<CAPTION>
                                                       MARCH 31, 2000    DECEMBER 31, 1999
----------------------------------------------------  ----------------  -------------------
<S>                                                   <C>               <C>
ASSETS
----------------------------------------------------
CURRENT ASSETS:
Cash . . . . . . . . . . . . . . . . . . . . . . . .  $           976   $              647
Accounts receivable - net. . . . . . . . . . . . . .            3,824                4,077
Inventories. . . . . . . . . . . . . . . . . . . . .            3,566                3,190
Other current assets . . . . . . . . . . . . . . . .              705                  624
                                                                        -------------------
Total current assets . . . . . . . . . . . . . . . .            9,071                8,538

PROPERTY AND EQUIPMENT - NET . . . . . . . . . . . .           10,550               11,013

INTANGIBLE ASSETS - NET. . . . . . . . . . . . . . .            8,087                8,205
                                                      ----------------  -------------------

TOTAL. . . . . . . . . . . . . . . . . . . . . . . .  $        27,708   $           27,756
                                                      ================  ===================

LIABILITIES AND STOCKHOLDERS' EQUITY
----------------------------------------------------

CURRENT LIABILITIES:
Accounts payable . . . . . . . . . . . . . . . . . .  $           674   $              544
Accrued expenses . . . . . . . . . . . . . . . . . .            2,165                2,117
Total current liabilities. . . . . . . . . . . . . .            2,839                2,661

NOTES PAYABLE. . . . . . . . . . . . . . . . . . . .            4,841                5,934

DEFERRED INCOME TAXES. . . . . . . . . . . . . . . .              354                  372
                                                      ----------------  -------------------

Total liabilities. . . . . . . . . . . . . . . . . .            8,034                8,967
                                                      ----------------  -------------------

STOCKHOLDERS' EQUITY:
Preferred stock - $.01 par value; authorized - 5,000
  shares; no shares issued or outstanding
Common stock - $.01 par value; authorized - 50,000
  shares; issued - March 31, 2000, 6,442 shares
  December 31, 1999, 6,453 shares. . . . . . . . . .               64                   64
Cumulative foreign currency translation adjustment .           (1,513)              (1,250)
Retained earnings. . . . . . . . . . . . . . . . . .           21,123               19,975
Total stockholders' equity . . . . . . . . . . . . .           19,674               18,789
                                                      ----------------  -------------------

TOTAL. . . . . . . . . . . . . . . . . . . . . . . .  $        27,708   $           27,756
                                                      ================  ===================
</TABLE>


              see  notes  to  consolidated  condensed  financial  statements
                                       -1-
<PAGE>



                  UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES
                  --------------------------------------------
               CONSOLIDATED CONDENSED STATEMENTS OF INCOME FOR THE
               ---------------------------------------------------
              THREE MONTHS ENDED MARCH 31, 2000 AND MARCH 31, 1999
              ----------------------------------------------------
                    (in thousands, except per share amounts)
                                   (unaudited)
<TABLE>
<CAPTION>
                                   THREE MONTHS ENDED
                                        MARCH 31,
                                        ---------
                                      2000    1999
                                     ------  ------
<S>                                  <C>     <C>
NET SALES . . . . . . . . . . . . .  $6,666  $7,018

COST OF SALES . . . . . . . . . . .   2,995   3,331
                                     ------  ------

GROSS MARGIN. . . . . . . . . . . .   3,671   3,687
                                     ------  ------

EXPENSES:

Selling, general and administrative   1,644   1,712
Research & development. . . . . . .     149     222
                                     ------  ------

Total . . . . . . . . . . . . . . .   1,793   1,934
                                     ------  ------

INCOME FROM OPERATIONS. . . . . . .   1,878   1,753

OTHER INCOME. . . . . . . . . . . .      38     115
                                     ------  ------

INCOME BEFORE INCOME TAX EXPENSE. .   1,916   1,868

INCOME TAX EXPENSE. . . . . . . . .     690     668
                                     ------  ------

NET INCOME. . . . . . . . . . . . .  $1,226  $1,200
                                     ======  ======

EARNINGS PER COMMON AND
  COMMON EQUIVALENT SHARE . . . . .  $ 0.19  $ 0.15
                                     ======  ======

EARNINGS PER COMMON SHARE
  ASSUMING FULL DILUTION. . . . . .  $ 0.19  $ 0.15
                                     ======  ======

SHARES OUTSTANDING - BASIC. . . . .   6,447   7,939
                                     ======  ======

SHARES OUTSTANDING - DILUTED. . . .   6,469   7,939
                                     ======  ======
</TABLE>


see notes to consolidated condensed financial statements

                                       -2-

<PAGE>



                  UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES
                  --------------------------------------------
                 CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
                 -----------------------------------------------
          FOR THE THREE MONTHS ENDED MARCH 31, 2000 AND MARCH 31, 1999
          ------------------------------------------------------------
                           (in thousands - unaudited)
<TABLE>
<CAPTION>

                                                                  MARCH 31,
                                                                   ---------
                                                                 2000      1999
                                                               --------  --------
<S>                                                            <C>       <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income. . . . . . . . . . . . . . . . . . . . . . . . . .  $ 1,226   $ 1,200
                                                               --------  --------
Adjustments to reconcile net income to net
    cash provided by operating activities:
    Depreciation and amortization . . . . . . . . . . . . . .      571       526
    (Recovery of)/Provision for losses on accounts receivable        4        (3)
    (Gain)/Loss on disposal of assets . . . . . . . . . . . .       (1)        1
    Deferred income taxes . . . . . . . . . . . . . . . . . .      (34)      (39)
Changes in operating assets and liabilities:
    Accounts receivable - trade . . . . . . . . . . . . . . .      405      (142)
    Accrued interest and other receivables. . . . . . . . . .     (191)      216
    Inventories . . . . . . . . . . . . . . . . . . . . . . .     (371)      291
    Prepaid expenses. . . . . . . . . . . . . . . . . . . . .      (65)      (63)
    Accounts payable. . . . . . . . . . . . . . . . . . . . .      138       108
    Accrued expenses. . . . . . . . . . . . . . . . . . . . .       57       164
    Deferred revenue. . . . . . . . . . . . . . . . . . . . .        0        (2)
                                                               --------  --------
Total adjustments . . . . . . . . . . . . . . . . . . . . . .      514     1,057
                                                               --------  --------
Net cash provided by operating activities . . . . . . . . . .    1,739     2,257
                                                               --------  --------

CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures for:
    Property and equipment. . . . . . . . . . . . . . . . . .     (125)     (178)
    Intangible assets . . . . . . . . . . . . . . . . . . . .     (100)       (1)
Proceeds from sale of property and equipment. . . . . . . . .        0         0
                                                               --------  --------
Net cash used in investing activities . . . . . . . . . . . .     (225)     (179)
                                                               --------  --------

CASH FLOWS FROM FINANCING ACTIVITIES:
Common stock purchased and retired. . . . . . . . . . . . . .      (78)   (1,455)
Decrease in note payable. . . . . . . . . . . . . . . . . . .   (1,093)   (1,384)
                                                               --------  --------
Net cash used in financing activities . . . . . . . . . . . .   (1,171)   (2,839)
                                                               --------  --------

Effect of exchange rate changes on cash . . . . . . . . . . .      (14)      (11)

NET INCREASE (DECREASE) IN CASH . . . . . . . . . . . . . . .      329      (772)

CASH AT BEGINNING OF PERIOD . . . . . . . . . . . . . . . . .      647     1,367
                                                               --------  --------

CASH AT END OF PERIOD . . . . . . . . . . . . . . . . . . . .  $   976   $   595
                                                               ========  ========

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
  Cash paid during the period for income taxes. . . . . . . .  $   463   $   375
  Interest. . . . . . . . . . . . . . . . . . . . . . . . . .  $    96   $    40
</TABLE>


            see notes to consolidated condensed financial statements

                                       -3-

<PAGE>

                          UTAH MEDICAL PRODUCTS, INC.
                          ----------------------------
              NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
              ----------------------------------------------------
                                   (unaudited)

(1)     The  unaudited  financial statements presented herein have been prepared
in  accordance  with the instructions to form 10-Q and do not include all of the
information  and  note  disclosures  required  by  generally accepted accounting
principles.  These  statements  should be read in conjunction with the financial
statements and notes included in the Utah Medical Products, Inc. ("UTMD" or "the
Company")  annual  report  on  form  10-K  for the year ended December 31, 1999.
Although  the  accompanying  financial  statements  have  not  been  examined by
independent  accountants  in  accordance  with  generally  accepted  auditing
standards,  in  the opinion of management, such financial statements include all
adjustments  (consisting  only  of  normal  recurring  adjustments) necessary to
summarize  fairly  the  Company's  financial position and results of operations.

(2)     Inventories  at  March  31,  2000  and  December 31, 1999 (in thousands)
consisted  of  the  following:


                                             March  31,             December 31,
                                                2000                    1999
                                              --------               ---------
     Finished  goods                         $   1,170                $   846
     Work-in-process                             1,000                    962
     Raw  materials                              1,396                  1,382
                                                 -----                  -----
     Total                                      $3,566                 $3,190
                                                ======                 ======


(3)     The  Company has adopted SFAS No. 130, "Reporting Comprehensive Income."
This  standard  requires  companies  to  disclose  certain changes in equity not
represented  in  net income such as foreign currency translation adjustments and
unrealized  gains/losses  on  available-for-sale  securities.  These  items  are
components  of  other  comprehensive  income  which,  when  added to net income,
represent  total  comprehensive  income.  The Company translates the currency of
its  Ireland  subsidiary which comprises the only element of other comprehensive
income.  Total  comprehensive  income  for the quarter ending March 31, 2000 was
(in  thousands)  $962.

(4)     In  June  1999,  the  Financial Accounting Standards Board (FASB) issued
Statement  of  Financial  Accounting  Standards  (SFAS) No. 137, "Accounting for
Derivative Instruments and Hedging Activities- Deferral of the Effective Date of
FASB  Statement  No.  133."  SFAS  133  establishes  accounting  and  reporting
standards for derivative instruments and requires recognition of all derivatives
as  assets or liabilities in the statement of financial position and measurement
of  those instruments at fair value.  SFAS 133 is now effective for fiscal years
beginning after June 15, 2000.  UTMD believes that the adoption of SFAS 133 will
not  have  a  material  effect  on  the  financial  statements  of  the Company.

(5)     Forward-Looking  Information

          This  report  contains  certain  forward-looking  statements  and
information  relating to the Company that are based on the beliefs of management
as  well  as  assumptions  made  by,  and  information  currently  available to,
management.  When  used  in  this  document,  the words "anticipate," "believe,"
"should,"  "project," "estimate," "expect," "intend" and similar expressions, as
they  relate  to  the  Company  or  its  management,  are  intended  to identify
forward-looking  statements.  Such  statements  reflect  the current view of the
Company  respecting  future  events  and  are  subject  to  certain  risks,
uncertainties,  and  assumptions,  including  the  risks and uncertainties noted
throughout  the  document.  Although  the  Company  has  attempted  to  identify
important  factors  that  could  cause  the actual results to differ materially,
there  may be other factors that cause the forward statement not to come true as
anticipated,  believed, projected, expected, or intended.  Should one or more of
these risks or uncertainties materialize, or should underlying assumptions prove
incorrect,  actual  results may differ materially from those described herein as
anticipated,  believed,  projected,  estimated,  expected,  or  intended.

          General  risk  factors  that may impact the Company's revenues include
the  market  acceptance  of  competitive  products,  obsolescence  caused by new
technologies,  the  possible  introduction  by  competitors of new products that
claim  to  have  many  of the advantages of UTMD's products at lower prices, the
timing  and  market  acceptance  of UTMD's own new product introductions, UTMD's
ability  to  efficiently  manufacture its products, including the reliability of

                                       -4-

<PAGE>

suppliers,  success in gaining access to important global distribution channels,
marketing  success  of  UTMD's  distribution  and  sales  partners,  budgetary
constraints,  the  timing of regulatory approvals for newly introduced products,
third party reimbursement, and access to U.S. hospital customers, as that access
is  increasingly  constrained  by  group  purchasing  decisions.
     Risk  factors,  in addition to the risks outlined in the previous paragraph
that  may  impact  the  Company's assets and liabilities, as well as cash flows,
include  risks  inherent to companies manufacturing products used in health care
including  claims  resulting  from the improper use of devices and other product
liability claims, defense of the Company's intellectual property, productive use
of  assets  in  generating  revenues,  management  of  working capital including
inventory  levels  required  to meet delivery commitments at a minimum cost, and
timely  collection  of  accounts  receivable.
     Additional  risk  factors  that may affect non-operating income include the
continuing viability of the Company's technology license agreements, actual cash
and investment balances, asset dispositions, and acquisition activities that may
require  external  funding.

(6)     Events  subsequent  to  March  31,  2000

          On  April  14,  2000,  UTMD  entered  into  a  new unsecured revolving
line-of-credit  agreement  with  Key  Bank  N.A.  which  replaces  its  prior
line-of-credit.  Under  the  agreement, the Company may borrow up to $14,500,000
at  a  floating  interest  rate tied to Prime Rate or LIBOR, at UTMD's election.
Significant  financial  covenants under the line require the Company to maintain
minimum  Current  and  Total  Funded  Debt  to  EBITDA  ratios.

                                       -5-

<PAGE>

ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF  OPERATIONS

General
          UTMD  manufactures  and  markets a well-established range of specialty
medical  devices.  The  general  characteristics  of  UTMD's  business  have not
materially  changed over the last several reporting periods.  The Company's Form
10-K  Annual  Report  for  the  year ended December 31, 1999 provides a detailed
description  of  products,  technologies,  markets,  regulatory issues, business
initiatives,  resources  and  business risks, among other details, and should be
read  in  conjunction with this report.  Because of the relatively short span of
time,  results  for  any  given three month period in comparison with a previous
three  month period may not be indicative of comparative results for the year as
a  whole.  Dollar  amounts  in  the  report  are  expressed in thousands, except
per-share  amounts  and  where  otherwise  noted.

Analysis  of  Results  of  Operations
     a)     First  Quarter  (1Q)  Overview
          Sales  in  1Q  2000  declined  5%  from 1Q 1999, due to lower sales of
obstetrics  products  in  the  U.S.,  and lower sales of OEM products worldwide.
Despite  the  lower  sales,  operating  profits  improved 7% due to record gross
profit  margins  and  tightly controlled operating expenses.  Earnings per share
(EPS) were up 25% compared to 1Q 1999 due to share repurchases.  With its strong
cash  flow,  UTMD was able to reduce its long term debt balance by $1.1 million,
allow  finished goods inventories to increase by $0.4 million during a period of
softer  than  expected demand, and repurchase another 11,300 shares of its stock
in  1Q  2000.

     b)     Revenues
          In  1Q  2000,  sales  to  customers  outside  the  U.S. grew 24% while
domestic  sales,  excluding  component  sales  to Baxter, declined 9%.  Sales of
components  to  Baxter  declined  79%  to  $32  in 1Q 2000 from $148 in 1Q 1999.
     In  the  U.S.,  obstetrics  product  sales  decreased  12%  due  to  end of
millennium  overstocking  and  increased  competition,  while  electro surgery/
gynecology/  urology product sales and neonatal product sales remained about the
same.  Blood  pressure  monitoring  components  excluding  sales  to Baxter/ OEM
molding  products  declined  20% as a result of fluctuation in customer ordering
patterns,  for  no  apparent  reasons.
     Foreign sales of obstetrics products, electro surgery/ gynecology products,
neonatal products and blood pressure monitoring (BPM) components and accessories
increased  17%,  92%,  117%  and  14%  respectively.
     Global  obstetrics product sales which decreased 11% in 1Q 2000 represented
46% of total sales.  Obstetrics sales were $3,041 in 1Q 2000, compared to $3,402
in 1Q 1999. Global gynecology/ electro surgery/ urology product sales which grew
9%  in 1Q 2000  represented 17% of total revenues.  Gyn/ES/Uro sales were $1,125
in 1Q 2000, compared to $1,036 in 1Q 1999.  Neonatal product sales which grew 6%
represented  13%  of  total sales.  Neonatal product sales were $872 in 1Q 2000,
compared  to  $826  in  1Q  1999.  BPM  and accessories sales including sales to
Baxter  which  declined 7% represented 24% of global consolidated 1Q 2000 sales.
Sales of BPM and accessories products in 1Q 2000 were $1,629, compared to $1,753
in  1Q  1999.

     c)     Gross  Profit
          UTMD's  gross  profit  margin  (GPM)  in 1Q 2000 was 55.1% compared to
52.5%  in  1Q  1999.  Gross  margin  improvements  were  led  by  control  of
manufacturing  overhead costs and lower direct materials costs.  During the rest
of  2000,  offsetting  influences  are  expected  to result in GPM of about 54%.
Expected favorable influences include growth in sales activity without a similar
increase in overhead expenses and a continued emphasis on reengineering products
to  reduce  costs.  Unfavorable  influences  are  expected  to  be  continued
competitive  pressure  on pricing and higher wage rates and other benefits costs
for  production employees.  UTMD management believes that consistently achieving
an  average  GPM  above  50%  is crucial to successfully support the significant
sales  and  marketing,  research  and  development,  and administrative expenses
associated  with  an  innovative  medical device company in a highly complex and
competitive  marketplace.

     d)     Operating  Profit

          1Q  2000  operating  profits  increased 7% to $1,878 from $1,753 in 1Q
1999.  Total  operating  expenses, including sales and marketing (S&M) expenses,
research  and  development  (R&D)  expenses and general and administrative (G&A)
expenses,  were  $1,793 or 26.9% of sales in 1Q 2000 compared to $1,934 or 27.6%

                                       -6-

<PAGE>

of  sales in 1Q 1999.  Reducing operating expenses as a percentage of sales with
lower  sales  is  a  significant  achievement  for  the  quarter.
     S&M  expenses  in  1Q  2000 were $877 or 13.2% of sales compared to $973 or
13.9%  of  sales  in  1Q  1999.  S&M  expenses  are  dominated  by  the costs of
promoting,  selling  and  providing  customer  support of UTMD's direct sales of
products  in  the U.S.  Although total 1Q 2000 sales decreased 5%, including OEM
and  overseas  sales  where  third  parties  underwrite significant S&M costs of
selling  UTMD's products, the U.S. direct sales portion decreased 9%.  Total S&M
expenses  were reduced 10% in conjunction with managing expenses relative to the
actual  performance  of  UTMD's  domestic  direct  S&M  resources.
     R&D expenses in 1Q 2000 were $148 or 2.2% of sales compared to $222 or 3.2%
of  sales  in  1Q  1999.  The  mid-year  1999  termination  of  internal efforts
committed to UTMD's fetal pH monitoring project, which represented about half of
R&D  spending in 1H 1999, was responsible for the decline.  Current R&D projects
include  continuing  development  of the Fowler Endocurette, enhancements to the
Gesco  neonatal  product  line,  and  improvements  to  UTMD's other established
products.  R&D  improvements  in  materials  and configuration of components was
evident  in  UTMD's improved GPMs.   At UTMD, R&D resources are kept involved in
the  direct  support of manufacturing, as UTMD finds it makes long-term sense to
keep  its  most  technical  people  involved with products and the processes for
making  them  throughout  their  life  cycles.
     G&A  expenses  in  1Q  2000 were $767 or 11.5% of sales compared to $739 or
10.5%  of  1Q  1999 sales.  Year 2000 G&A expenses are expected to be consistent
with  1999,  and  in  1Q  2000  were  within expected limits of normal quarterly
fluctuation.

     e)  Non-operating  income
          Royalty income from licensing UTMD's technology to other companies was
partially  offset  by  interest  expenses  and  bank  fees  on  the  revolving
line-of-credit in 1Q 2000.  Non-operating income in 1Q 2000 was $38, compared to
$115  in 1Q 1999.  Royalties received in 1Q 2000 were $44 less than in the prior
year's  quarter.  Interest  expenses  and  bank  fees  associated  with  the
line-of-credit  were  $98  in  1Q  2000  compared to $43 in 1Q 1999.  Assuming a
minimal  change  in  current  interest  rates and no new borrowing to finance an
extraordinary  capital  requirement,  net  non-operating income will increase in
each  successive  quarter  in  2000  as  the  line-of-credit  balance  declines.

     f)     Earnings  Before  Income  Taxes
          1Q  2000  earnings  before  income  taxes  (EBT)  were  28.7% of sales
compared  to  26.6% in 1Q 1999.  UTMD was able to increase EBT 3% relative to 1Q
1999 even though sales were down 5% because of improvement accomplished in gross
margin  combined  with  tight  control of operating expenses.  If sales activity
increases,  UTMD  expects  it  can  increase  EBT  at  a  faster  rate.

     g)     Net  Income  and  EPS
          UTMD's  after  tax  net  income expressed as a percentage of sales was
18.4%  for  1Q  2000  compared  to  17.1%  for 1Q 1999.  Net income expressed in
dollars  was  up  2%  at  $1,226,  compared to $1,200 in 1Q 1999.  The effective
income  tax  rate  in  1Q  2000  was  36.0%  compared  to  35.8%  in  1Q  1999.
     Diluted  1Q  2000  earnings per share (EPS) were up 25% to $.19 compared to
$.15  in 1Q 1999.  1Q 2000 weighted average number of diluted common shares (the
number  used to calculate diluted EPS) were 6,469 compared to 7,939 shares in 1Q
1999.  Actual  outstanding  common  shares  as of the end of 1Q 2000 were 6,442.
UTMD's trailing twelve months' EPS were $.81, up 35% from the prior twelve month
period  of  time.

     h)     Return  on  Shareholders'  Equity  (ROE)
          ROE  in  1Q  2000  was  22%  compared  to  19%  in  1Q  1999.

     i)     Cash  flows
          EBITDA is a measure of UTMD's ability to generate cash.  First quarter
2000  EBITDA  was $2,584, up from $2,438 in 1Q 1999, or as a ratio of sales, 39%
in  1Q  2000  compared to 35% in 1Q 1999.  UTMD used EBITDA to allow purchase of
$125  worth  of  assets  to  sustain  facilities,  equipment and tooling in good
working order, investment of $100 in new intangible assets, repurchase $78 worth
of it shares, as well as a decrease in its bank revolving line-of-credit balance
by  $1,093  during  1Q  2000.

                                       -7-

<PAGE>

          Net  cash  provided by operating activities, including adjustments for
depreciation  and  other  non-cash  operating  expenses,  along  with changes in
working  capital, totaled $1,739 in 1Q 2000, compared to $2,257 in 1Q 1999.  Net
working  capital  changes used $28 in 1Q 2000 cash compared to providing $572 in
1Q  1999,  with  the  largest change (adjusted for exchange rate changes) coming
from  higher finished goods inventories, which UTMD increased in lieu of cutting
production rates in order to maintain production efficiencies during a period of
temporary  soft  demand.
     Financing  activities  in  1Q  2000  used cash of $1,093 to reduce the bank
line-of-credit.  In addition, 11,300 shares of stock were repurchased at a total
cost  of  $78.  No stock was issued in the first quarter of either 2000 or 1999.
On  April  14,  2000, UTMD entered into a new unsecured revolving line-of-credit
agreement with Key Bank N.A. which replaces its prior line-of-credit.  Under the
agreement,  the Company may borrow up to $14,500,000 at a floating interest rate
tied  to  Prime  Rate  or  LIBOR,  at UTMD's election.  Covenants under the line
include  maintaining  minimum  Current  and  Total Funded Debt to EBITDA ratios.
     Management  believes  that  capital spending in 1Q 2000 was at a sufficient
rate  to  sustain  current  operations.  In  addition  to  sustaining  capital
expenditures,  UTMD  expects  to  use cash during the rest of 2000 for selective
infusions of technological, marketing or product manufacturing rights to broaden
the  Company's product offerings, for continued share repurchases when the price
of  the  stock  remains  undervalued,  and, if available for a reasonable price,
acquisitions  that  strategically  fit  UTMD's  business  and  are  accretive to
performance.  The  revolving  credit line will continue to be used for liquidity
when  the  timing of acquisitions or repurchases of stock require a large amount
of  cash  in  a  short  period  of  time.

     j)     Assets  and  Liabilities
          1Q  2000  ending total assets were essentially the same as at December
31,  1999.  Current  assets  increased  as a result of higher inventory and cash
balances  while  net  fixed  assets  declined  because  depreciation  exceeded
replacement  purchases.  Net  intangible assets declined because amortization of
goodwill  and  intellectual  property exceeded new acquisitions.  1Q 2000 ending
net  intangible  assets  represent  29%  of  total  assets.
     Average  inventory turns decreased in 1Q 2000 to 3.5 times, compared to 3.8
times  in  1999,  due  to  lower  sales  and  higher finished goods inventories.
Inventories  were allowed to increase $376 during 1Q 2000 based on UTMD's belief
that  the  sales decrease was temporary.  If sales increase during the remainder
of  2000,  management  expects to be able to achieve its target of 4.0 inventory
turns.  March  31, 2000 accounts receivable (A/R) balances declined 6%, slightly
more  than  sales.  Calculated  days  in  receivables  at 49 for 1Q 2000 did not
change from year-end 1999.  The working capital increase of $355 was essentially
due  to  the  increase  in  finished  goods  inventory.
     At  the  end  of 1Q 2000, UTMD's total debt ratio decreased to 29% of total
assets  from  32% at the end of 1999, due to the reduction in the line-of-credit
balance.

     k)     Management's  Outlook.
          UTMD has built and continues to successfully defend a dominant medical
device  market  franchise  in  the  most  special  areas of hospitals caring for
mothers  and  their  babies,  with  innovative  and  highly  effective products.
     UTMD's  small but effective direct U.S. sales team continues to evolve as a
key  resource  for achieving UTMD's objectives to help identify clinician needs,
responsively  provide  excellent  solutions  for  those needs, and assure timely
support  for customers' use of UTMD's solutions.  In the remaining part of 2000,
UTMD  will  investigate ways to expand its U.S. sales coverage through improving
its  relationships  with  national distributors who can access customers in ways
not  available  to  UTMD's  direct  sales  force,  through partnering with other
manufacturers  where  a  broader product offering can leverage marketing efforts
and  through  initiatives  to  effectively  employ  Internet  technology.
Internationally,  UTMD  will  continue  to build on the success of its effective
distribution  partners.
     Consistent  with its view of the nature of the medical device industry as a
whole,  UTMD  believes  it  can  achieve  significant  top  line  growth through
selective  acquisitions,  and  plans  to  do  so  without  diluting  shareholder
interest.  In UTMD's case, management does not intend to achieve top line growth
at  the  expense  of  bottom line growth.  Internal R&D will continue to be used
primarily  to  improve  and  augment  existing  or  acquired  product  lines.

                                       -8-




<PAGE>
                           PART II - OTHER INFORMATION

ITEM  6.  EXHIBITS  AND  REPORTS  ON  FORM  8-K

  a)     Exhibits:

               SEC
Exhibit  #     Reference  #     Title  of  Document
----------     ------------     -------------------

     1             10           Business  Loan  Agreement, dated April 14, 2000
                                Between Utah Medical Products, Inc.  and  Key
                                Bank  National  Association

     2             27           Financial  data  schedule


  b)     Reports  on  Form  8-K:

           During the quarter ended March 31, 2000, the Company filed no reports
            on  Form  8-K.



                                   SIGNATURES

     Pursuant  to  the requirements of the Securities Exchanges Act of 1934, the
registrant  has  duly  caused  this  report  to  be  signed on its behalf by the
undersigned  thereunto  duly  authorized.


                                          UTAH  MEDICAL  PRODUCTS,  INC.
                                          ------------------------------
                                                  REGISTRANT





Date:                                      By:
                                           ------------------------------
                                           Kevin  L.  Cornwell
                                           CEO  and  CFO


                                       -9-